Dapagliflozin showed 🚫no significant improvement in health status post-#TAVI in the DapaTAVI substudy. Although it may reduce death or worsening #HeartFailure in patients with #vhdAS, further research of pts w/ residual symptoms needed. 📰 Journal Scan: https://t.co/PuyTkyikuw

#JACCCaseReports offers a look at "Severe Aortic Valve Stenosis During Pregnancy: Role of Multidisciplinary Pregnancy Heart Team to Guide Decision-Making" https://t.co/FpT43LBX2W #ACCCardioOB #CardioOB #CardioObstetrics #vhdAS

Among patients with severe #vhdAS at risk for surgery with highly calcified aortic valves, #SAVR is linked with lower risks of all-cause mortality, paravalvular regurgitation & #HeartFailure hospitalization than TAVI, new research shows.

New in #JACCINT: International cohort 🌍 of severe AS pts shows BAV-0 after #TAVR had better 5-year survival 📈 vs BAV-1 & TAV. Valve choice matters: self-expanding valves outperformed balloon-expandable valves for long-term outcomes ⏳✅ https://t.co/Z70YZXUXfR #vhdAS

Here's a case of a 71-year-old woman with a history of giant cell arteritis aortitis and severe bicuspid AS with low-flow, low-gradient who successfully underwent #TAVI. The patient presented with acute #HFrEF. Get the details: https://t.co/aEGmqGncyr #JACCCaseReports #vhdAS

Discover the latest advancements in the field of #amyloidosis! 📚 From genomic screening to transthyretin amyloidosis and aortic stenosis, #JACCCardioOnc's Amyloidosis Hub covers it all. https://t.co/nOJSWzYd7Y #ACCMidEast #CardioOnc #ATTR #vhdAS @DrBonnieKy @ACCinTouch

#JACCBTS study reveals the diversity of miRNAs propagated in circulating EVs in plasma from aortic stenosis patients. Get the details: https://t.co/pZ1Ct2KdQT #vhdAS

#JACCAdvances study presents an #AI-driven model that forecasts the transition from mild/moderate AS to severe disease utilizing solely echocardiographic data, facilitating earlier, tailored decisions. https://t.co/ggySE5Dm1C #ESCCongress #WCCardio #vhdAS @Itelman_Edi

Volume-flow discordance occurs in nearly one-third of patients w/ #vhdAS post #TAVR & offers superior prognostic value over existing stroke volume index & TFR thresholds, according to a recent study being presented at #ESCCongress. More: https://t.co/FF8ajcRbSs #JACCAsia

#EVOLUTLowRisk_Trial #TAVR 🆚️ #SAVR #vhdAS #ACC23 #WCCardio @ACCinTouch 🔗 ➡️ https://t.co/qYmnFQPW5d

According to a new analysis, #SAVR has better 5-year survival outcomes than TAVI for patients with #vhdAS. Learn more:

Compared w/ tricuspid aortic valves (TAV) & bicuspid aortic valves type 1 (BAV-1; 1 raphe), BAV type 0 (BAV-0; no raphe) was associated w/ a better long-term prognosis among patients w/ severe #vhdAS undergoing #TAVR procedures. Read more: https://t.co/KgdYzDV1w0 #JACCINT

DAPA-TAVI: The #SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening #HeartFailure in older adults w/ #vhdAS undergoing TAVI, resulting in a 28% relative risk ↘️. #ACC25 More: https://t.co/xG7oBp1xBE #cvSurg

#PCRLV 2023 🇬🇧 Late breaking aortic trials #vhdAS #cvVHD #TAVI #TAVR ❤️

An 88-year-old man with AS underwent transfemoral #TAVR with a nonretrievable device. During valve insertion, the extra support wire was withdrawn from the LV. Attempts to recross the valve were unsuccessful. https://t.co/Q9pmaF9Fxr #JACCCaseReports #vhdAS

Outcomes of #TAVR in Asymptomatic or Minimally Symptomatic Aortic Stenosis #TAVR in minimally symptomatic #AS shows higher 1-yr survival & improved health status Vs. more symptomatic pts! Even small improvements matter. https://t.co/ZgTyMY4Uw0 #vhdAS #CardioTwitter #CardioEd

In this low-intermediate risk cohort, urgent #TAVR offered comparable procedural success & adjusted 30-day mortality to elective TAVR but was associated w/ higher 12-month mortality, supporting its role as a feasible short-term option https://t.co/JLMGZQYgRL #JACCAdvances #vhdAS

Drs. @JRWinterfield & William G. Stevenson discuss a case of combined #TAVR + VT ablation for VT storm with severe AS, and share tips on submitting cases to #JACCCaseReports Submit your research here: https://t.co/dU6cFU3Xsj #epAblation #vhdAS

A recent study found that patients with asymptomatic severe #vhdAS saw a consistent benefit with early #TAVR treatment, regardless of baseline LV health. Learn more: https://t.co/CSxcyVimJe #ASE2025 #JACC